Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART
The integrase strand transfer inhibitor, dolutegravir (DTG), is widely used in first- and second-line antiretroviral therapy (ART) regimens in South Africa. We describe an adult with virological failure on second-line tenofovir/lamivudine/dolutegravir (TLD2) and rapid emergence of DTG resistance within 3 months, while receiving rifapentine-based tuberculosis preventive therapy.
Authors
- Yukteshwar Sookrajh (ORCID: https://orcid.org/0000-0001-9029-5153)
- Nigel Garrett (ORCID: https://orcid.org/0000-0002-4530-234X)
- Paul K. Drain (ORCID: https://orcid.org/0000-0002-9569-4097)
- Pravi Moodley (ORCID: https://orcid.org/0000-0002-9946-8783)
- Mahomed‐Yunus S. Moosa (ORCID: https://orcid.org/0000-0001-6191-4023)
- Richard Lessells (ORCID: https://orcid.org/0000-0003-0926-710X)
- Jienchi Dorward (ORCID: https://orcid.org/0000-0001-6072-1430)
- K Naidoo (ORCID: https://orcid.org/0009-0002-8835-5190)
Institutions
- National Health Laboratory Service (ZA)
- University of Washington (US)
- Centre for the AIDS Programme of Research in South Africa (ZA)
- eThekwini Municipality (ZA)
- University of Oxford (GB)
- University of KwaZulu-Natal (ZA)
Publication Details
- Journal
- Southern African Journal of HIV Medicine
- Published
- 2025-04-23
- DOI
- https://doi.org/10.4102/sajhivmed.v26i1.1701
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- University of Washington
- National Institutes of Health